ketamine has been researched along with Age-Related Memory Disorders in 81 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this respect, ketamine and tetrahydrocannabinol (cannabis) are coming under increasing scrutiny as models for schizophrenia." | 8.83 | Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits. ( Fletcher, PC; Honey, GD, 2006) |
| "This study aimed to determine effects of the resveratrol on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice." | 8.31 | Resveratrol plays neuroprotective role on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice. ( Farkhakfar, A; Hassanpour, S; Zendehdel, M, 2023) |
| "Schizophrenia is a serious neuropsychiatric disorder characterized by the presence of positive symptoms (hallucinations, delusions, and disorganization of thought and language), negative symptoms (abulia, alogia, and affective flattening), and cognitive impairment (attention deficit, impaired declarative memory, and deficits in social cognition)." | 7.01 | Ketamine as a pharmacological tool for the preclinical study of memory deficit in schizophrenia. ( Picazo, O; Roldán, GR; Suárez Santiago, JE, 2023) |
| "Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats." | 5.48 | Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. ( Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y, 2018) |
| "As adjunctive medication, ketamine can attenuate learning and memory impairment, especially for short-term memory, caused by ECT performed under propofol anesthesia." | 5.24 | Effect of Low Dose of Ketamine on Learning Memory Function in Patients Undergoing Electroconvulsive Therapy-A Randomized, Double-Blind, Controlled Clinical Study. ( Chen, J; Chen, Q; Hao, X; Li, X; Luo, Q; Meng, H; Min, S; Peng, L, 2017) |
| "A major physical harm is ketamine induced ulcerative cystitis which, although its aetiology is unclear, seems particularly associated with chronic, frequent use of the drug." | 4.88 | Ketamine use: a review. ( Curran, HV; Morgan, CJ, 2012) |
| " In this respect, ketamine and tetrahydrocannabinol (cannabis) are coming under increasing scrutiny as models for schizophrenia." | 4.83 | Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits. ( Fletcher, PC; Honey, GD, 2006) |
| "This study aimed to determine effects of the resveratrol on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice." | 4.31 | Resveratrol plays neuroprotective role on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice. ( Farkhakfar, A; Hassanpour, S; Zendehdel, M, 2023) |
| "Crocin's ability to counteract hypermotility, stereotypies and ataxia induced by ketamine was evaluated in a motor activity cage." | 3.80 | Crocins, the active constituents of Crocus Sativus L., counteracted ketamine-induced behavioural deficits in rats. ( Georgiadou, G; Grivas, V; Pitsikas, N; Tarantilis, PA, 2014) |
| "Ketamine has been used in humans to model cardinal symptoms of schizophrenia, including working memory impairments and behavioral disorganization." | 3.76 | Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. ( Castner, SA; Roberts, BM; Schmidt, CJ; Seymour, PA; Williams, GV, 2010) |
| "Schizophrenia is a serious neuropsychiatric disorder characterized by the presence of positive symptoms (hallucinations, delusions, and disorganization of thought and language), negative symptoms (abulia, alogia, and affective flattening), and cognitive impairment (attention deficit, impaired declarative memory, and deficits in social cognition)." | 3.01 | Ketamine as a pharmacological tool for the preclinical study of memory deficit in schizophrenia. ( Picazo, O; Roldán, GR; Suárez Santiago, JE, 2023) |
| "Posttraumatic stress disorder (PTSD), a disabling and chronic condition after exposure to an extreme traumatic event, affects approximately 8% of the population worldwide." | 1.91 | Age-related impairment in fear memory extinction is restored by ketamine in middle-aged mice. ( Li, H; Shao, H; Wang, H; Xue, Q; Zhao, Y, 2023) |
| "Ketamine is an anesthetic agent able to produce psychotic-like symptoms through the antagonism of the glutamatergic N-methyl-d-aspartic acid (NMDA) receptors (NMDARs)." | 1.72 | The 5-HT6R agonist E-6837 and the antagonist SB-271046 reverse the psychotic-like behaviors induced by ketamine. ( Picazo Picazo, O; Roldán Roldán, G; Suárez-Santiago, JE, 2022) |
| "Ketamine anesthesia was administered to rats in the second trimester of pregnancy, and two behavioral tests were performed, including contextual and cued fear conditioning test (CFC) and Morris water maze (MWM)." | 1.56 | Ketamine exerts neurotoxic effects on the offspring of pregnant rats via the Wnt/β-catenin pathway. ( Chang, T; Gao, L; Liu, W; Wang, Q; Zhang, X; Zhao, J, 2020) |
| "The treatment of major depressive disorder (MDD) is still a challenge." | 1.56 | Guanosine fast onset antidepressant-like effects in the olfactory bulbectomy mice model. ( de Almeida, RF; Elisabetsky, E; Pocharski, CB; Rodrigues, ALS; Souza, DO, 2020) |
| "Gallic acid (GA) is a natural free radical "scavenger." | 1.56 | Binge and Subchronic Exposure to Ketamine Promote Memory Impairments and Damages in the Hippocampus and Peripheral Tissues in Rats: Gallic Acid Protective Effects. ( Brum, GF; Burger, ME; Metz, VG; Milanesi, LH; Rosa, HZ; Rosa, JLO; Rossato, DR, 2020) |
| "Ketamine is an anesthetic agent that antagonizes N-methyl-d-aspartate receptors, inducing psychotic-like symptoms in healthy humans and animals." | 1.56 | Repeated ketamine administration induces recognition memory impairment together with morphological changes in neurons from ventromedial prefrontal cortex, dorsal striatum, and hippocampus. ( Bautista-Orozco, LÁ; Orozco-Suárez, S; Picazo, O; Suárez-Santiago, JE; Vega-García, A, 2020) |
| "Ketamine is a non-competitive NMDA antagonist with effect on cognitive performance and plasticity." | 1.51 | Episodic-like memory impairment induced by sub-anaesthetic doses of ketamine. ( Barbosa, FF; de Souza, IBMB; Lima, RH; Meurer, YDSR; Pugliane, KC; Silva, RH; Tavares, PM, 2019) |
| "Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats." | 1.48 | Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. ( Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y, 2018) |
| "It also attenuated hyper-locomotion and memory deficits induced by chronic injection of ketamine in mice." | 1.46 | Probable mechanisms involved in the antipsychotic-like activity of methyl jasmonate in mice. ( Aluko, OM; Annafi, OS; Eduviere, AT; Omorogbe, O; Umukoro, S, 2017) |
| "Ketamine has been reported to cause neonatal neurotoxicity via a neuronal apoptosis mechanism; however, no in vivo research has reported whether ketamine could affect postnatal neurogenesis in the hippocampal dentate gyrus (DG)." | 1.43 | Ketamine Affects the Neurogenesis of the Hippocampal Dentate Gyrus in 7-Day-Old Rats. ( Hao, T; Huang, H; Liu, CM; Sun, J; Wang, D; Wu, YQ; Xu, CM, 2016) |
| "Vortioxetine is a multimodal-acting antidepressant that is hypothesized to exert its therapeutic activity through 5-HT reuptake inhibition and modulation of several 5-HT receptors." | 1.43 | Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. ( du Jardin, KG; Elfving, B; Liebenberg, N; Müller, HK; Sanchez, C; Wegener, G, 2016) |
| "N,N-dimethylglycine (DMG) is a derivative of the amino acid glycine and is used as a dietary supplement." | 1.43 | N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice. ( Chan, MH; Chen, HH; Chen, YC; Lee, MY; Lin, JC, 2016) |
| "Ketamine users are often poly-substance users." | 1.39 | Cognitive impairments in poly-drug ketamine users. ( Chan, F; Lau, CG; Liang, HJ; Tang, A; Tang, WK; Ungvari, GS, 2013) |
| "The cognitive and memory deficits are persistent, and their underlying cellular mechanisms remain unclear." | 1.39 | Acute ketamine induces hippocampal synaptic depression and spatial memory impairment through dopamine D1/D5 receptors. ( Cao, J; Duan, TT; Tan, JW; Xu, L; Yuan, Q; Zhou, QX, 2013) |
| "Ketamine and alcohol were given by intraperitoneal injection and intragastric administration, respectively, 1 time per day, for 14 days." | 1.38 | [Effects of ketamine and alcohol on learning and memory impairment in mice]. ( Bian, SZ; Ding, F; Gu, ZL; Guo, CY; Jiang, XG; Wu, XX; Yang, MY, 2012) |
| "Ketamine has been utilized to investigate NMDA receptor-mediated learning and memory and to model disorders such as schizophrenia." | 1.38 | Examination of ketamine-induced deficits in sensorimotor gating and spatial learning. ( Bolton, MM; Heaney, CF; Kinney, JW; Murtishaw, AS; Sabbagh, JJ, 2012) |
| " Assessments of psychological wellbeing showed greater dissociative symptoms in frequent users and a dose-response effect on delusional symptoms, with frequent users scoring higher than infrequent, abstinent users and non-users, respectively." | 1.36 | Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. ( Curran, HV; Morgan, CJ; Muetzelfeldt, L, 2010) |
| "Ketamine has been used to model cognitive and behavioral symptoms of schizophrenia." | 1.36 | Reversal of ketamine-induced working memory impairments by the GABAAalpha2/3 agonist TPA023. ( Arriza, JL; Castner, SA; Christian, EP; Mrzljak, L; Roberts, JC; Williams, GV, 2010) |
| "These memory deficits were not state dependent, because ketamine treatment at both encoding and retrieval only increased the number of errors during the test session." | 1.35 | Revealing past memories: proactive interference and ketamine-induced memory deficits. ( Chrobak, JJ; Hinman, JR; Sabolek, HR, 2008) |
| "Ketamine is an N-methyl-d-aspartate (NMDA)-receptor antagonist that is increasingly being used as a recreational drug." | 1.32 | Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users. ( Curran, HV; Maitland, CH; Morgan, CJ; Riccelli, M, 2004) |
| "Ketamine is a dissociative anaesthetic that is also a drug of abuse." | 1.32 | Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. ( Curran, HV; Monaghan, L; Morgan, CJ, 2004) |
| "Ketamine-treated rats, however, displayed markedly more damage within the entorhinal cortices and amygdalohippocampal area." | 1.31 | Normal spatial memory following postseizure treatment with ketamine: selective damage attenuates memory deficits in brain-damaged rodents. ( Cook, LL; O'Connor, RP; Persinger, MA; Santi, SA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.23) | 18.7374 |
| 1990's | 1 (1.23) | 18.2507 |
| 2000's | 15 (18.52) | 29.6817 |
| 2010's | 50 (61.73) | 24.3611 |
| 2020's | 14 (17.28) | 2.80 |
| Authors | Studies |
|---|---|
| Browne, CA | 1 |
| Wulf, HA | 1 |
| Jacobson, ML | 1 |
| Oyola, MG | 1 |
| Wu, TJ | 1 |
| Lucki, I | 1 |
| Suárez-Santiago, JE | 2 |
| Roldán Roldán, G | 1 |
| Picazo Picazo, O | 1 |
| Pitsikas, N | 8 |
| Zoupa, E | 1 |
| Gravanis, A | 1 |
| Rajagopal, L | 2 |
| Huang, M | 1 |
| He, W | 1 |
| Ryan, C | 1 |
| Elzokaky, A | 1 |
| Banerjee, P | 1 |
| Meltzer, HY | 2 |
| Suárez Santiago, JE | 1 |
| Roldán, GR | 1 |
| Picazo, O | 2 |
| Katsanou, L | 1 |
| Fragkiadaki, E | 1 |
| Kampouris, S | 1 |
| Konstanta, A | 1 |
| Vontzou, A | 1 |
| Zhao, Y | 1 |
| Shao, H | 1 |
| Wang, H | 2 |
| Li, H | 2 |
| Xue, Q | 1 |
| Farkhakfar, A | 1 |
| Hassanpour, S | 1 |
| Zendehdel, M | 1 |
| Zhang, X | 1 |
| Zhao, J | 1 |
| Chang, T | 1 |
| Wang, Q | 1 |
| Liu, W | 1 |
| Gao, L | 1 |
| de Almeida, RF | 1 |
| Pocharski, CB | 1 |
| Rodrigues, ALS | 1 |
| Elisabetsky, E | 1 |
| Souza, DO | 1 |
| Brum, GF | 1 |
| Rosa, HZ | 1 |
| Rossato, DR | 1 |
| Rosa, JLO | 1 |
| Metz, VG | 1 |
| Milanesi, LH | 1 |
| Burger, ME | 1 |
| Orozco-Suárez, S | 1 |
| Vega-García, A | 1 |
| Bautista-Orozco, LÁ | 1 |
| Tarantilis, PA | 2 |
| Yang, W | 1 |
| Chini, M | 1 |
| Pöpplau, JA | 1 |
| Formozov, A | 1 |
| Dieter, A | 1 |
| Piechocinski, P | 1 |
| Rais, C | 1 |
| Morellini, F | 1 |
| Sporns, O | 1 |
| Hanganu-Opatz, IL | 1 |
| Wiegert, JS | 1 |
| Morena, M | 1 |
| Berardi, A | 1 |
| Peloso, A | 1 |
| Valeri, D | 1 |
| Palmery, M | 1 |
| Trezza, V | 1 |
| Schelling, G | 1 |
| Campolongo, P | 1 |
| Onaolapo, OJ | 1 |
| Paul, TB | 1 |
| Onaolapo, AY | 1 |
| Annafi, OS | 1 |
| Aluko, OM | 1 |
| Eduviere, AT | 1 |
| Omorogbe, O | 1 |
| Umukoro, S | 1 |
| Koh, MT | 2 |
| Shao, Y | 2 |
| Rosenzweig-Lipson, S | 1 |
| Gallagher, M | 1 |
| Gacsályi, I | 1 |
| Móricz, K | 1 |
| Gigler, G | 1 |
| Wellmann, J | 1 |
| Nagy, K | 1 |
| Ling, I | 1 |
| Barkóczy, J | 1 |
| Haller, J | 1 |
| Lambert, JJ | 1 |
| Szénási, G | 1 |
| Spedding, M | 1 |
| Antoni, FA | 1 |
| Simões, LR | 1 |
| Sangiogo, G | 1 |
| Tashiro, MH | 1 |
| Generoso, JS | 1 |
| Faller, CJ | 1 |
| Dominguini, D | 1 |
| Mastella, GA | 1 |
| Scaini, G | 1 |
| Giridharan, VV | 1 |
| Michels, M | 1 |
| Florentino, D | 1 |
| Petronilho, F | 1 |
| Réus, GZ | 1 |
| Dal-Pizzol, F | 1 |
| Zugno, AI | 1 |
| Barichello, T | 1 |
| Zhang, Y | 3 |
| Sha, R | 1 |
| Wang, K | 1 |
| Yan, B | 1 |
| Zhou, N | 1 |
| Koychev, I | 1 |
| William Deakin, JF | 1 |
| El-Deredy, W | 1 |
| Haenschel, C | 1 |
| Sanku, RKK | 1 |
| John, JS | 1 |
| Salkovitz, M | 1 |
| Ilies, MA | 1 |
| Walker, EA | 1 |
| de Souza, IBMB | 1 |
| Meurer, YDSR | 1 |
| Tavares, PM | 1 |
| Pugliane, KC | 1 |
| Lima, RH | 1 |
| Silva, RH | 1 |
| Barbosa, FF | 1 |
| Chan, KW | 1 |
| Lee, TM | 1 |
| Siu, AM | 1 |
| Wong, DP | 1 |
| Kam, CM | 1 |
| Tsang, SK | 1 |
| Chan, CC | 1 |
| Duan, TT | 1 |
| Tan, JW | 1 |
| Yuan, Q | 1 |
| Cao, J | 1 |
| Zhou, QX | 1 |
| Xu, L | 1 |
| Nakako, T | 1 |
| Murai, T | 1 |
| Ikejiri, M | 1 |
| Ishiyama, T | 1 |
| Taiji, M | 1 |
| Ikeda, K | 1 |
| Hoffman, KL | 1 |
| Basurto, E | 1 |
| Wei, YB | 1 |
| Yang, JR | 1 |
| Wood, D | 1 |
| Cote, AL | 1 |
| Rolland, B | 1 |
| Cottencin, O | 1 |
| Liang, HJ | 1 |
| Lau, CG | 1 |
| Tang, A | 1 |
| Chan, F | 1 |
| Ungvari, GS | 1 |
| Tang, WK | 1 |
| Georgiadou, G | 1 |
| Grivas, V | 1 |
| Markou, A | 1 |
| Jiang, XL | 1 |
| Du, BX | 1 |
| Chen, J | 2 |
| Liu, L | 1 |
| Shao, WB | 1 |
| Song, J | 1 |
| Honsberger, MJ | 1 |
| Taylor, JR | 1 |
| Corlett, PR | 2 |
| Zhu, X | 1 |
| Li, P | 1 |
| Hao, X | 2 |
| Wei, K | 1 |
| Min, S | 2 |
| Luo, J | 1 |
| Xie, F | 1 |
| Jin, J | 1 |
| Khanegheini, A | 1 |
| Nasehi, M | 1 |
| Zarrindast, MR | 1 |
| Burgdorf, JS | 1 |
| Moskal, JR | 1 |
| Trevlopoulou, A | 1 |
| Touzlatzi, N | 1 |
| Sherwood, A | 1 |
| Smith, DR | 1 |
| Huang, H | 1 |
| Liu, CM | 1 |
| Sun, J | 1 |
| Hao, T | 1 |
| Xu, CM | 1 |
| Wang, D | 1 |
| Wu, YQ | 1 |
| Jin, LH | 1 |
| Song, YY | 1 |
| Shen, Y | 1 |
| Ji, W | 1 |
| Zhang, MZ | 1 |
| Qi, Z | 1 |
| Yu, GP | 1 |
| Tretter, F | 1 |
| Pogarell, O | 1 |
| Grace, AA | 1 |
| Voit, EO | 1 |
| du Jardin, KG | 1 |
| Liebenberg, N | 1 |
| Müller, HK | 1 |
| Elfving, B | 1 |
| Sanchez, C | 1 |
| Wegener, G | 1 |
| Lin, JC | 1 |
| Chan, MH | 1 |
| Lee, MY | 1 |
| Chen, YC | 1 |
| Chen, HH | 1 |
| Chen, Q | 1 |
| Peng, L | 1 |
| Meng, H | 1 |
| Luo, Q | 1 |
| Li, X | 1 |
| Ranganathan, M | 1 |
| DeMartinis, N | 1 |
| Huguenel, B | 1 |
| Gaudreault, F | 1 |
| Bednar, MM | 1 |
| Shaffer, CL | 2 |
| Gupta, S | 1 |
| Cahill, J | 1 |
| Sherif, MA | 1 |
| Mancuso, J | 1 |
| Zumpano, L | 1 |
| D'Souza, DC | 1 |
| Morgan, CJ | 5 |
| Muetzelfeldt, L | 2 |
| Curran, HV | 6 |
| De La Torre, R | 1 |
| Castner, SA | 3 |
| Arriza, JL | 1 |
| Roberts, JC | 1 |
| Mrzljak, L | 1 |
| Christian, EP | 1 |
| Williams, GV | 3 |
| Roberts, BM | 2 |
| Holden, DE | 1 |
| Seymour, PA | 2 |
| Menniti, FS | 1 |
| Schmidt, CJ | 2 |
| Boultadakis, A | 2 |
| Peng, S | 1 |
| Ren, B | 1 |
| Zhang, J | 1 |
| Valentim, AM | 2 |
| Venâncio, C | 1 |
| Summavielle, T | 1 |
| Antunes, LM | 2 |
| Ribeiro, PO | 1 |
| Rodrigues, P | 1 |
| Olsson, IA | 1 |
| Bolton, MM | 2 |
| Heaney, CF | 2 |
| Sabbagh, JJ | 2 |
| Murtishaw, AS | 2 |
| Magcalas, CM | 1 |
| Kinney, JW | 2 |
| Yang, MY | 1 |
| Ding, F | 1 |
| Jiang, XG | 1 |
| Wu, XX | 1 |
| Gu, ZL | 1 |
| Guo, CY | 1 |
| Bian, SZ | 1 |
| Huang, L | 1 |
| Liu, Y | 1 |
| Jin, W | 1 |
| Ji, X | 1 |
| Dong, Z | 1 |
| Sun, L | 1 |
| Li, Q | 2 |
| Liu, D | 1 |
| Jiang, H | 1 |
| Pan, F | 1 |
| Yew, DT | 1 |
| Honey, RA | 1 |
| Turner, DC | 2 |
| Honey, GD | 3 |
| Sharar, SR | 1 |
| Kumaran, D | 1 |
| Pomarol-Clotet, E | 2 |
| McKenna, P | 1 |
| Sahakian, BJ | 1 |
| Robbins, TW | 1 |
| Fletcher, PC | 3 |
| Micallef, J | 1 |
| Tardieu, S | 1 |
| Gentile, S | 1 |
| Fakra, E | 1 |
| Jouve, E | 1 |
| Sambuc, R | 1 |
| Blin, O | 1 |
| Ahn, KH | 1 |
| Youn, T | 1 |
| Cho, SS | 1 |
| Ha, TH | 1 |
| Ha, KS | 1 |
| Kim, MS | 1 |
| Kwon, JS | 1 |
| Riccelli, M | 1 |
| Maitland, CH | 1 |
| Monaghan, L | 2 |
| O'loughlin, C | 1 |
| Wang, JH | 1 |
| Fu, Y | 1 |
| Wilson, FA | 1 |
| Ma, YY | 1 |
| McDaniel, WW | 1 |
| Sahota, AK | 1 |
| Vyas, BV | 1 |
| Laguerta, N | 1 |
| Hategan, L | 1 |
| Oswald, J | 1 |
| Gilles, C | 1 |
| Luthringer, R | 1 |
| Chrobak, JJ | 1 |
| Hinman, JR | 1 |
| Sabolek, HR | 1 |
| Newcomer, JW | 1 |
| Farber, NB | 1 |
| Jevtovic-Todorovic, V | 1 |
| Selke, G | 1 |
| Melson, AK | 1 |
| Hershey, T | 1 |
| Craft, S | 1 |
| Olney, JW | 1 |
| Umbricht, D | 1 |
| Schmid, L | 1 |
| Koller, R | 1 |
| Vollenweider, FX | 1 |
| Hell, D | 1 |
| Javitt, DC | 1 |
| Santi, SA | 1 |
| Cook, LL | 1 |
| Persinger, MA | 1 |
| O'Connor, RP | 1 |
| Sprints, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder[NCT05357040] | Phase 2 | 172 participants (Anticipated) | Interventional | 2021-06-30 | Recruiting | ||
| A Double-blind Randomised, Placebo-controlled Study of Adjunctive Ketamine Anaesthesia in ECT (Electroconvulsive Therapy)[NCT00680433] | Phase 4 | 83 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy ---a Randomized Control Double-Blind Clinical Trial[NCT02305394] | Phase 4 | 132 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Predictive Coding Abnormalities in Psychosis: EEG and fMRI[NCT03068806] | 202 participants (Actual) | Observational | 2014-12-01 | Completed | |||
| Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome[NCT02304302] | Phase 2 | 160 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
This is a measure of adaptive functioning that integrates information from 13 different domains (e.g., gross motor, social interaction, eating, toileting, dressing, personal self-care, etc.). It is in a questionnaire format, which a caregiver can complete while the participant is being tested. Standard scores for all indices will be derived from age norms that extend from birth to age 80, as these were used as dependent variables. We report here on the Broad Independence Score recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the SIB-R Score Scale in this study was -24 (this number is below 0 because -24 was the minimum value for the worst performing participant in the trial) and the maximum value of this scale is 153; higher scores mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 6.88 |
| Memantine | 3.23 |
The primary efficacy measure is focused on episodic memory. The CVLT-II short form assesses supraspan word learning ability as an index of episodic verbal long-term memory. We hypothesize that treatment with memantine will produce significant improvements in this test. The main dependent variable selected, based on prior literature was the total number of target items correct summed across learning trials 1-4. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). Scale Range: from 0 to 36; higher scores represent better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 3.3 |
| Memantine | 3.49 |
This is a measure of non-verbal memory that requires the participant to learn associations between an abstract visual pattern and its location. Two dependent variables have been selected: Total number of items correct on the first trial of each stage, and total number of stages completed. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the PAL Memory Score Scale is 0 and the maximum value is 21; higher scores mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 1 |
| Memantine | 0.67 |
This is a measure of non-verbal memory. Total number correct across the two series of items presented was used as the dependent variable. We used the PRM total scale in this study, which represents the sum of the PRM correct scores (ranging from 0 to 24) and the PRM delayed scores (ranging from 0 to 24). Therefore, the range of the PRM total scale is from 0 to 48; higher values mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.45 |
| Memantine | -0.05 |
This is a measure of rote short-term verbal memory. Total number of items correct were used as the dependent variable. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value for this scale is 0 and the maximum value is 38; higher scores mean a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.03 |
| Memantine | -0.01 |
This measure is a computerized version of the Corsi Blocks task, a long-standing neuropsychological test. The main dependent variables selected for this test was the span length, which is the longest sequence of numbers recalled accurately. The minimum value of the Spatial Span Length Score Scale is 0 and the maximum value is 9; higher scores mean better outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.13 |
| Memantine | 0.03 |
"The test requires participants to search under a series of colored boxes to locate a blue token hidden underneath one of them. During a series of trials, the participant is told that the token will be in a new location each time and that they should not go back to a location he or she has looked in previously. The main dependent variable was the total number of errors (between errors), which indexes the number of times a participant went back to a box where a token had already been found, lower scores mean better performance. The minimum value of the Spatial Working Memory scale is 0 and the maximum value is 137 (which was computed as the equivalent to -4 standard deviations from the mean of this measure); higher scores mean worse outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2)." (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | -0.09 |
| Memantine | -1.4 |
"This is a measure of inhibitory control, often used as a marker for prefrontal-striatal function integrity. Specifically, it measures the participant's ability to inhibit pre-potent behavioral responses that have been established by provision of prior go or no-go cues in a classical conditioning paradigm. The main dependent variables selected was speed of response of execution to Go targets. The minimum value of the speed of response of execution to Go targets is 280 milliseconds (ms) and the maximum value is 1000 ms; higher scores mean worse outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2)." (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | ms (Mean) |
|---|---|
| Placebo | -2.52 |
| Memantine | 0.22 |
This test provides a measure of non-verbal reasoning ability that requires subjects to visually inspect a matrix of 4 or 9 pictures that has a missing piece. Participants have to infer a rule or pattern in the stimuli and select the appropriate response from a range of 4-6 possibilities. Since age norms are not available for individuals older than 17y11m, the ability score will be used as the dependent variable. This is an intermediate score based on Rasch modeling that corrects for different items set being administered to participants. The minimum value of the DAS-II Rasch Score Scale is 0 and the maximum value is 153; higher scores mean better outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.75 |
| Memantine | 2.66 |
This is a measure of receptive semantics, whereby the participant is asked to point to a picture (out of 4) that corresponds to a word spoken by the examiner. As this test has a 0.85 correlation with composite measures of Verbal IQ (i.e. from the Wechsler Intelligence Scale series), it can be used in conjunction with the Matrices subtest to estimate overall intellectual functioning. The total number of items correct was used as the dependent variable, following the administration manual's rules for basals and ceilings. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value for this scale is 0 and the maximum value is 192, higher scores mean a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 4.46 |
| Memantine | 5.63 |
This is a measure of receptive syntax skills (Bishop, 1983). Participants are asked to point to a picture (out of 4) that corresponds to a phrase or sentence spoken by the examiner. The total number of items correct (rather than blocks passed) will be used as the dependent variable, following the administration manual's ceiling rule. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the scores is 0 and the maximum value is 40; with higher scores considered to be a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 0.49 |
| Memantine | 0.89 |
Incidence of adverse events was monitored by clinical history, physical examinations, electrocardiograms (ECGs), clinical laboratory tests, the Screen for Childhood Anxiety Related Emotional Disorders (SCARED). Here, we report the analysis of the effect of memantine treatment on QTc intervals because of its clinical importance for this analysis for potential drug toxicity. QTc intervals ≥ 450 ms are generally considered long, and drug-induced QTc interval prolongations ≥ 60 ms are generally considered clinically relevant. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
| Intervention | ms (Mean) |
|---|---|
| Placebo | -1.30 |
| Memantine | -0.11 |
4 reviews available for ketamine and Age-Related Memory Disorders
| Article | Year |
|---|---|
Ketamine as a pharmacological tool for the preclinical study of memory deficit in schizophrenia.
Topics: Cognitive Dysfunction; Humans; Ketamine; Memory Disorders; Receptors, N-Methyl-D-Aspartate; Schizoph | 2023 |
Ketamine use: a review.
Topics: Abdominal Pain; Acute Disease; Anesthetics, Dissociative; Animals; Behavior, Addictive; Child; Chron | 2012 |
Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits.
Topics: Age Factors; Animals; Attention; Cannabis; Evoked Potentials; Humans; Ketamine; Memory Disorders; Me | 2006 |
Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs.
Topics: Apomorphine; Cognition Disorders; Dopamine Agonists; Excitatory Amino Acid Antagonists; GABA Modulat | 2007 |
5 trials available for ketamine and Age-Related Memory Disorders
| Article | Year |
|---|---|
Effect of Low Dose of Ketamine on Learning Memory Function in Patients Undergoing Electroconvulsive Therapy-A Randomized, Double-Blind, Controlled Clinical Study.
Topics: Adolescent; Adult; Aged; Anesthesia; Anesthetics, Intravenous; Asian People; Depressive Disorder, Ma | 2017 |
Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory.
Topics: Adolescent; Adult; Analysis of Variance; Double-Blind Method; Female; Humans; Ketamine; Male; Memory | 2003 |
[Effects of a subanaesthetic dose of ketamine on emotional and behavioral state in healthy subjects].
Topics: Adult; Anesthetics, Dissociative; Behavior; Cognition; Cross-Over Studies; Double-Blind Method; Emot | 2003 |
The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia.
Topics: Adolescent; Adult; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; | 2006 |
Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.
Topics: Adult; Animals; Cognition; Depression, Chemical; Dose-Response Relationship, Drug; Double-Blind Meth | 1999 |
72 other studies available for ketamine and Age-Related Memory Disorders
| Article | Year |
|---|---|
Long-term increase in sensitivity to ketamine's behavioral effects in mice exposed to mild blast induced traumatic brain injury.
Topics: Anesthetics, Dissociative; Animals; Ataxia; Behavior, Animal; Blast Injuries; Brain Concussion; Brai | 2022 |
The 5-HT6R agonist E-6837 and the antagonist SB-271046 reverse the psychotic-like behaviors induced by ketamine.
Topics: Animals; Antipsychotic Agents; Humans; Indoles; Ketamine; Memory Disorders; Mice; Mice, Inbred ICR; | 2022 |
The novel dehydroepiandrosterone derivative BNN27 counteracts the impairing effects of anesthetic ketamine on rats' non-spatial and spatial recognition memory.
Topics: Anesthetics; Animals; Dehydroepiandrosterone; Ketamine; Memory Disorders; Rats; Rats, Wistar; Recogn | 2022 |
Repeated administration of rapastinel produces exceptionally prolonged rescue of memory deficits in phencyclidine-treated mice.
Topics: Animals; Ketamine; Mammals; Memory Disorders; Mice; Oligopeptides; Phencyclidine | 2022 |
The Nitric Oxide (NO) Donor Molsidomine Counteract Social Withdrawal and Cognition Deficits Induced by Blockade of the NMDA Receptor in the Rat.
Topics: Animals; Clozapine; Cognition; Cognitive Dysfunction; Ketamine; Memory Disorders; Molsidomine; Nitri | 2023 |
Age-related impairment in fear memory extinction is restored by ketamine in middle-aged mice.
Topics: Animals; Extinction, Psychological; Fear; Ketamine; Long-Term Potentiation; Memory Disorders; Mice; | 2023 |
Resveratrol plays neuroprotective role on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice.
Topics: Animals; Disease Models, Animal; Ketamine; Male; Memory Disorders; Mice; Oxidative Stress; Resveratr | 2023 |
Ketamine exerts neurotoxic effects on the offspring of pregnant rats via the Wnt/β-catenin pathway.
Topics: Analgesics; Animals; beta Catenin; Cognitive Dysfunction; Down-Regulation; Female; Hippocampus; Keta | 2020 |
Guanosine fast onset antidepressant-like effects in the olfactory bulbectomy mice model.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder, Major; Disease Mod | 2020 |
Binge and Subchronic Exposure to Ketamine Promote Memory Impairments and Damages in the Hippocampus and Peripheral Tissues in Rats: Gallic Acid Protective Effects.
Topics: Anesthetics, Dissociative; Animals; Antioxidants; Brain-Derived Neurotrophic Factor; Catalase; Galli | 2020 |
Repeated ketamine administration induces recognition memory impairment together with morphological changes in neurons from ventromedial prefrontal cortex, dorsal striatum, and hippocampus.
Topics: Animals; Corpus Striatum; Dendritic Spines; Dose-Response Relationship, Drug; Excitatory Amino Acid | 2020 |
Crocins, the Bioactive Components of
Topics: Anesthetics; Animals; Carotenoids; Crocus; Humans; Ketamine; Memory; Memory Disorders; Rats | 2021 |
Anesthetics fragment hippocampal network activity, alter spine dynamics, and affect memory consolidation.
Topics: Anesthesia; Anesthetics; Animals; Electrophysiological Phenomena; Female; Fentanyl; Hippocampus; Iso | 2021 |
Effects of ketamine, dexmedetomidine and propofol anesthesia on emotional memory consolidation in rats: Consequences for the development of post-traumatic stress disorder.
Topics: Animals; Avoidance Learning; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Dr | 2017 |
Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Anxiety; Behavior, Animal; Benzodiazepines; Do | 2017 |
Probable mechanisms involved in the antipsychotic-like activity of methyl jasmonate in mice.
Topics: Acetates; Animals; Antioxidants; Antipsychotic Agents; Brain; Bromocriptine; Cyclopentanes; Disease | 2017 |
Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Cognition Disorders; Disease Models, Animal | 2018 |
Behavioural pharmacology of the α5-GABA
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Benzodiazepines; Cognition; Dose-Response Relat | 2017 |
Maternal immune activation induced by lipopolysaccharide triggers immune response in pregnant mother and fetus, and induces behavioral impairment in adult rats.
Topics: Animals; Behavior, Animal; Blood-Brain Barrier; Brain; Cytokines; Embryo, Mammalian; Excitatory Amin | 2018 |
Protective effects of tetrahydropalmatine against ketamine-induced learning and memory injury via antioxidative, anti-inflammatory and anti-apoptotic mechanisms in mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Berberine Alkaloids; Ketamine; Male; Maz | 2018 |
Effects of Acute Ketamine Infusion on Visual Working Memory: Event-Related Potentials.
Topics: Adult; Cognition; Evoked Potentials; Evoked Potentials, Visual; Excitatory Amino Acid Antagonists; F | 2017 |
Potential learning and memory disruptors and enhancers in a simple, 1-day operant task in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adjuvants, Anesthesia; Animals; Conditioning, Operant; Disea | 2018 |
Episodic-like memory impairment induced by sub-anaesthetic doses of ketamine.
Topics: Anesthetics, Dissociative; Animals; CA1 Region, Hippocampal; Dose-Response Relationship, Drug; Excit | 2019 |
Effects of chronic ketamine use on frontal and medial temporal cognition.
Topics: Attention; Case-Control Studies; Cognition Disorders; Dose-Response Relationship, Drug; Excitatory A | 2013 |
Acute ketamine induces hippocampal synaptic depression and spatial memory impairment through dopamine D1/D5 receptors.
Topics: Anesthetics, Dissociative; Animals; Benzazepines; CA1 Region, Hippocampal; Dose-Response Relationshi | 2013 |
Effects of a dopamine D1 agonist on ketamine-induced spatial working memory dysfunction in common marmosets.
Topics: Animals; Benzazepines; Callithrix; Dopamine Agonists; Ketamine; Maze Learning; Memory Disorders; Mem | 2013 |
One-trial object recognition memory in the domestic rabbit (Oryctolagus cuniculus) is disrupted by NMDA receptor antagonists.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory A | 2013 |
'Ketamine-induced ulcerative cystitis' is perhaps better labelled 'ketamine-induced uropathy'.
Topics: Anesthetics, Dissociative; Animals; Cystitis; Humans; Ketamine; Male; Memory Disorders; Substance-Re | 2013 |
Ketamine and damage to the urinary tract.
Topics: Anesthetics, Dissociative; Animals; Cystitis; Humans; Ketamine; Male; Memory Disorders; Substance-Re | 2013 |
'Addiction' in adolescence: who is really losing control?
Topics: Anesthetics, Dissociative; Animals; Cystitis; Humans; Ketamine; Male; Memory Disorders; Substance-Re | 2013 |
Cognitive impairments in poly-drug ketamine users.
Topics: Anxiety; Case-Control Studies; Cognition Disorders; Depression; Excitatory Amino Acid Antagonists; E | 2013 |
Crocins, the active constituents of Crocus Sativus L., counteracted ketamine-induced behavioural deficits in rats.
Topics: Animals; Antipsychotic Agents; Ataxia; Carotenoids; Ketamine; Male; Memory Disorders; Motor Activity | 2014 |
The metabotropic glutamate 2/3 receptor agonist LY379268 counteracted ketamine-and apomorphine-induced performance deficits in the object recognition task, but not object location task, in rats.
Topics: Amino Acids; Animals; Apomorphine; Bridged Bicyclo Compounds, Heterocyclic; Dopamine Agonists; Dose- | 2014 |
MicroRNA-34a negatively regulates anesthesia-induced hippocampal apoptosis and memory impairment through FGFR1.
Topics: Anesthetics, Dissociative; Animals; Animals, Newborn; Apoptosis; Behavior, Animal; CA1 Region, Hippo | 2014 |
Memories reactivated under ketamine are subsequently stronger: A potential pre-clinical behavioral model of psychosis.
Topics: Animals; Caudate Nucleus; Conditioning, Classical; Disease Models, Animal; Excitatory Amino Acid Ant | 2015 |
Ketamine-mediated alleviation of electroconvulsive shock-induced memory impairment is associated with the regulation of neuroinflammation and soluble amyloid-beta peptide in depressive-like rats.
Topics: Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Calcium-Binding Proteins; Depression; Elec | 2015 |
The modulatory effect of CA1 GABAb receptors on ketamine-induced spatial and non-spatial novelty detection deficits with respect to Ca(2+).
Topics: Analysis of Variance; Animals; Baclofen; CA1 Region, Hippocampal; Calcium; Calcium Channel Blockers; | 2015 |
GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.
Topics: Animals; Cognition; Disease Models, Animal; Excitatory Amino Acid Antagonists; Ketamine; Male; Memor | 2016 |
The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Excitatory Amino Acid Antagonists; Ketamine | 2016 |
Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia.
Topics: Amphetamine; Animals; Conditioning, Classical; Disease Models, Animal; Fear; Hippocampus; Interneuro | 2016 |
Ketamine Affects the Neurogenesis of the Hippocampal Dentate Gyrus in 7-Day-Old Rats.
Topics: Anesthetics, Dissociative; Animals; Apoptosis; Astrocytes; Bromodeoxyuridine; Cell Movement; Cell Pr | 2016 |
Post-Exposure Exercise Fails to Ameliorate Memory Impairment Induced by Propofol and Ketamine in Developing Rats.
Topics: Anesthesia; Animals; Body Weight; Conditioning, Psychological; Female; Hippocampus; Immunohistochemi | 2016 |
A heuristic model for working memory deficit in schizophrenia.
Topics: Brain; Computer Simulation; gamma-Aminobutyric Acid; Glutamic Acid; Heuristics; Humans; Ketamine; Me | 2016 |
Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Disease | 2016 |
N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice.
Topics: Acoustic Stimulation; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Respo | 2016 |
Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242.
Topics: Adult; Cognitive Dysfunction; Double-Blind Method; Female; Healthy Volunteers; Humans; Ketamine; Mal | 2017 |
Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls.
Topics: Adolescent; Adult; Analgesics; Child; Cognition Disorders; Dissociative Disorders; Dose-Response Rel | 2009 |
Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study.
Topics: Adult; Cognition Disorders; Delusions; Depressive Disorder; Dissociative Disorders; Dose-Response Re | 2010 |
Commentary on Morgan et al. (2010): ketamine abuse: first medical evidence of harms we should confront.
Topics: Delusions; Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; Illicit Drugs; Ketamine; | 2010 |
Reversal of ketamine-induced working memory impairments by the GABAAalpha2/3 agonist TPA023.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drug Interactions; GABA-A Receptor Agon | 2010 |
Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Animals, Ne | 2010 |
Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists.
Topics: Animals; Cognition Disorders; Dopamine Agonists; Female; Humans; Ketamine; Macaca mulatta; Male; Mem | 2010 |
Effects of the nitric oxide synthase inhibitor L-NAME on recognition and spatial memory deficits produced by different NMDA receptor antagonists in the rat.
Topics: Animals; Dizocilpine Maleate; Drug Interactions; Ketamine; Male; Maze Learning; Memory Disorders; NG | 2010 |
Anesthetic ketamine counteracts repetitive mechanical stress-induced learning and memory impairment in developing mice.
Topics: Anesthetics; Animals; Avoidance Learning; Blotting, Western; Brain-Derived Neurotrophic Factor; Hipp | 2011 |
Anesthetic ketamine impairs rats' recall of previous information: the nitric oxide synthase inhibitor N-nitro-L-arginine methylester antagonizes this ketamine-induced recognition memory deficit.
Topics: Anesthetics, Dissociative; Animals; Enzyme Inhibitors; Ketamine; Male; Memory Disorders; Mental Reca | 2011 |
Importance of body temperature and clinical data in behavioral and anesthesia studies.
Topics: Animals; Ketamine; Male; Memory Disorders; Mental Recall; NG-Nitroarginine Methyl Ester; Nitric Oxid | 2012 |
Apoptotic neurodegeneration and spatial memory are not affected by sedative and anaesthetics doses of ketamine/medetomidine combinations in adult mice.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Animals; Apoptosis; Behavior, Animal; Brain; Disea | 2012 |
Deficits in emotional learning and memory in an animal model of schizophrenia.
Topics: Analysis of Variance; Animals; Brain; Conditioning, Classical; Disease Models, Animal; Excitatory Am | 2012 |
[Effects of ketamine and alcohol on learning and memory impairment in mice].
Topics: Acetylcholine; Alcohols; Animals; Brain; Drug Synergism; Ketamine; Male; Maze Learning; Memory; Memo | 2012 |
Examination of ketamine-induced deficits in sensorimotor gating and spatial learning.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Dose-Response Relationship, Drug; Excitatory Am | 2012 |
Ketamine potentiates hippocampal neurodegeneration and persistent learning and memory impairment through the PKCγ-ERK signaling pathway in the developing brain.
Topics: Analgesics; Analysis of Variance; Animals; Animals, Newborn; Brain; Disease Models, Animal; Enzyme I | 2012 |
Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys.
Topics: Adolescent; Analysis of Variance; Animals; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal; | 2014 |
N-methyl-D-aspartate receptor in working memory impairments in schizophrenia: event-related potential study of late stage of working memory process.
Topics: Adult; Analysis of Variance; Evoked Potentials; Humans; Ketamine; Male; Memory; Memory Disorders; Re | 2003 |
Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users.
Topics: Adolescent; Adult; Analysis of Variance; Chi-Square Distribution; Female; Humans; Illicit Drugs; Ket | 2004 |
Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug.
Topics: Adult; Analgesics; Case-Control Studies; Chi-Square Distribution; Female; Humans; Ketamine; Language | 2004 |
Ketamine affects memory consolidation: differential effects in T-maze and passive avoidance paradigms in mice.
Topics: Animals; Avoidance Learning; Brain; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagoni | 2006 |
Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies.
Topics: Adult; Aged; Anesthetics, Dissociative; Depression; Electroconvulsive Therapy; Etomidate; Female; Hu | 2006 |
Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies.
Topics: Adult; Aged; Anesthetics, Dissociative; Depression; Electroconvulsive Therapy; Etomidate; Female; Hu | 2006 |
Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies.
Topics: Adult; Aged; Anesthetics, Dissociative; Depression; Electroconvulsive Therapy; Etomidate; Female; Hu | 2006 |
Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies.
Topics: Adult; Aged; Anesthetics, Dissociative; Depression; Electroconvulsive Therapy; Etomidate; Female; Hu | 2006 |
Revealing past memories: proactive interference and ketamine-induced memory deficits.
Topics: Animals; Ketamine; Male; Memory; Memory Disorders; Rats; Rats, Sprague-Dawley; Reaction Time; Recept | 2008 |
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.
Topics: Adult; Auditory Perception; Cognition; Cognition Disorders; Evoked Potentials; Female; Humans; Ketam | 2000 |
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.
Topics: Adult; Auditory Perception; Cognition; Cognition Disorders; Evoked Potentials; Female; Humans; Ketam | 2000 |
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.
Topics: Adult; Auditory Perception; Cognition; Cognition Disorders; Evoked Potentials; Female; Humans; Ketam | 2000 |
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.
Topics: Adult; Auditory Perception; Cognition; Cognition Disorders; Evoked Potentials; Female; Humans; Ketam | 2000 |
Normal spatial memory following postseizure treatment with ketamine: selective damage attenuates memory deficits in brain-damaged rodents.
Topics: Acepromazine; Animals; Behavior, Animal; Brain; Discrimination Learning; Dopamine Antagonists; Excit | 2001 |
In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users.
Topics: Adult; Affective Symptoms; Analysis of Variance; Cognition Disorders; Educational Status; Excitatory | 2001 |
[The mechanisms of memory disorders at the stages in its acquisition and fixation].
Topics: Amnesia; Animals; Avoidance Learning; Conditioning, Classical; Dose-Response Relationship, Drug; Fem | 1988 |